Tagged with S

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Italy The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who independently manage the budget for territorial pharmaceutical expenditure and evaluate regional access. According to many industry stakeholders, this lengthy process…

Italy Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European ophthalmic markets, breaking into orphan drugs and adding value in the glaucoma field—and is now seeing its ambitions become a…

Italy Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added medicines sector, and biotech. Massimo Scaccabarozzi, former President of Farmindustria; Michele Uda, director general of Egualia, and Leonardo Vingiani, managing…

Italy As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion in grants and loans over the lifetime of its National Recovery and Resilience Plan (NRRP). With respect to healthcare, the…

Egypt Roche Pharma General Manager in Egypt Mohamed Swilam shares his experience implementing a new operational model that is “challenging the status quo” of the pharma industry. He also explains the changing dynamics of the Egyptian pharma market – the fastest growing in the Middle East and Africa region – and…

Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region.   LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…

Switzerland Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its long-time CEO resign. But make no mistake: the Swiss giant is carefully guarding its position as one of the world’s…

Egypt The CEO of Egypt’s Universal Health Insurance Authority (UHIA) Hossam Sadek outlines the country’s strategy to provide healthcare coverage for the entire population by 2030, explains how the system will be financed, the first results from pilot programs across a few governorates, and the main challenges ahead, including a change…

LatAm Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and why countries in LatAm need to recognise obesity as the disease it is considering its heavy impact on patients’ lives…

China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics.   Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…

Global In only 21 years, the Global Fund has made remarkable progress in the fight to eliminate HIV, tuberculosis (TB), and malaria across the world, contributing to 44 million lives saved. Cross-sectoral partnerships that leverage the skills and capabilities of governments, multilateral agencies, bilateral partners, civil society groups, people affected by…